WO2008129624A1 - Dérivé de pyrazolopyridine-4-yl-pyrazolone, sel d'addition de celui-ci et inhibiteur de phosphodiestérase les contenant comme principe actif - Google Patents

Dérivé de pyrazolopyridine-4-yl-pyrazolone, sel d'addition de celui-ci et inhibiteur de phosphodiestérase les contenant comme principe actif Download PDF

Info

Publication number
WO2008129624A1
WO2008129624A1 PCT/JP2007/057905 JP2007057905W WO2008129624A1 WO 2008129624 A1 WO2008129624 A1 WO 2008129624A1 JP 2007057905 W JP2007057905 W JP 2007057905W WO 2008129624 A1 WO2008129624 A1 WO 2008129624A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolopyridine
active ingredient
same
addition salt
pyrazolone derivative
Prior art date
Application number
PCT/JP2007/057905
Other languages
English (en)
Japanese (ja)
Inventor
Yasushi Kohno
Naoki Ando
Koji Ochiai
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to PCT/JP2007/057905 priority Critical patent/WO2008129624A1/fr
Publication of WO2008129624A1 publication Critical patent/WO2008129624A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur un nouveau dérivé de pyrazolopyridine-4-yl-pyrazolone représenté par la formule générale suivante (1) : (1) (exemple spécifique : 6-(2-éthyl-7-méthoxy-pyrazolo[1,5-a]pyridine-4-yl)-4,4-diméthyl-2,4-dihydro-3-pyrazolone) est utile comme préparation pharmaceutique ayant un effet inhibiteur de phosphodiéstérase.
PCT/JP2007/057905 2007-04-10 2007-04-10 Dérivé de pyrazolopyridine-4-yl-pyrazolone, sel d'addition de celui-ci et inhibiteur de phosphodiestérase les contenant comme principe actif WO2008129624A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/057905 WO2008129624A1 (fr) 2007-04-10 2007-04-10 Dérivé de pyrazolopyridine-4-yl-pyrazolone, sel d'addition de celui-ci et inhibiteur de phosphodiestérase les contenant comme principe actif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/057905 WO2008129624A1 (fr) 2007-04-10 2007-04-10 Dérivé de pyrazolopyridine-4-yl-pyrazolone, sel d'addition de celui-ci et inhibiteur de phosphodiestérase les contenant comme principe actif

Publications (1)

Publication Number Publication Date
WO2008129624A1 true WO2008129624A1 (fr) 2008-10-30

Family

ID=39875172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/057905 WO2008129624A1 (fr) 2007-04-10 2007-04-10 Dérivé de pyrazolopyridine-4-yl-pyrazolone, sel d'addition de celui-ci et inhibiteur de phosphodiestérase les contenant comme principe actif

Country Status (1)

Country Link
WO (1) WO2008129624A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014448A1 (fr) * 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
JP2006117647A (ja) * 2004-09-22 2006-05-11 Kyorin Pharmaceut Co Ltd ハロゲノピラゾロピリジンピリダジノン誘導体とその付加塩及びそれを有効成分とするｐｄｅ阻害剤
JP2006169138A (ja) * 2004-12-14 2006-06-29 Kyorin Pharmaceut Co Ltd ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤
WO2006095666A1 (fr) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. Derive de pyrazolopyridine-4-yl-pyridazinone, sel d’addition de ce derive et inhibiteur des pde comprenant ce sel ou derive en tant qu’ingredient actif
JP2007091597A (ja) * 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014448A1 (fr) * 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
JP2006117647A (ja) * 2004-09-22 2006-05-11 Kyorin Pharmaceut Co Ltd ハロゲノピラゾロピリジンピリダジノン誘導体とその付加塩及びそれを有効成分とするｐｄｅ阻害剤
JP2006169138A (ja) * 2004-12-14 2006-06-29 Kyorin Pharmaceut Co Ltd ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤
WO2006095666A1 (fr) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. Derive de pyrazolopyridine-4-yl-pyridazinone, sel d’addition de ce derive et inhibiteur des pde comprenant ce sel ou derive en tant qu’ingredient actif
JP2007091597A (ja) * 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Similar Documents

Publication Publication Date Title
WO2008156094A1 (fr) Dérivé de pyridazinone et inhibiteur de la pde le contenant comme ingrédient actif
WO2007090141A3 (fr) Composés chimiques
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
EP2078721A3 (fr) Composés thiéno-pyrimidines ayant une activité fongicide
WO2009060835A1 (fr) Nouvelle petite molécule de liaison de l'ubiquitine
TN2011000245A1 (en) Organic compounds
WO2007023382A3 (fr) Composes de pyrimidine amino pyrazole, puissants inhibiteurs de kinase
WO2009057079A3 (fr) Nouveaux dérivés de pyrimidine
EP1864665A4 (fr) Agent immunosuppressif et agent anti-tumoral comprenant un compose heterocyclique en tant que principe actif
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2009016460A3 (fr) Composés pyrazoles
WO2007143705A3 (fr) Composés organiques
WO2009007751A3 (fr) Composé - 946
WO2006021454A3 (fr) Derives de pyrimidine
WO2005110410A3 (fr) Inhibiteurs de kinases en tant qu'agents therapeutiques
WO2008067119A3 (fr) Nouveaux composés
WO2005049616A8 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines a effet inhibiteur par rapport a la pde-5
WO2006021457A3 (fr) Derives de pyrimidine
WO2007058832A3 (fr) INHIBITEURS DES KINASES Tec
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
BRPI0514925A (pt) derivados de pirrol[2,3-c]piridina e processos para a preparação destes
WO2007146124A3 (fr) Inhibiteurs de pde5 substitué
WO2007009724A3 (fr) Derives de pyrazoline substitues cycloalkane, fabrication et utilisation comme medicaments
PL2170068T3 (pl) Sposób zwalczania owadów
WO2007064719A3 (fr) Formulations de quinolinones

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07741341

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07741341

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP